Amarin Corp Plc (AMRN)

[Durk 47]

STAY LONG & STAY STRONG!

Although it does not mention Vascepa by name, a pretty good article on page B3 of the WSJ today. In essence, it mentions a lot of these heart drugs like Repatha, Prualuent and Entresto have not done that well as they are only marginally effective and expensive Consequently, the insurance companies are resisting coverage with higher co-pays and more paperwork. Additionally 2 of the drugs are self injected which is less desirable than taking a Vascepa pill. Insurers will encourage patients to try the much less expensive and more effective alternative first. Price action should be pretty good next week as we get closer to FDA Approval.

Stay tuned!